Biomarkers /
SUFU
Overview
Suppressor of fused homolog (SUFU) is a gene that encodes a protein that functions as a negative regulator of the hedgehog signaling pathway. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as pleural cancer, skin cancer, and stomach cancer.
SUFU is altered in 0.87% of all cancers with colon adenocarcinoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, prostate adenocarcinoma, and conventional glioblastoma multiforme having the greatest prevalence of alterations [3].
The most common alterations in SUFU are SUFU Mutation (0.69%), SUFU Loss (0.16%), SUFU A25fs (0.05%), SUFU R123C (0.03%), and SUFU Amplification (0.02%) [3].
Clinical Trials
Significance of SUFU in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.